Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Thank you for sharing this Drug Metabolism & Disposition article. NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses. Your Email * Your Name * Send To * Enter multiple addresses on separate lines or separate them with commas.
Abstract Alterations in hepatic transporters have been identified in precirrhotic chronic liver diseases (CLDs) that result in pharmacokinetic variations causing adverse drug reactions (ADRs). However, the effect of CLD on the expression of renal transporters is unknown despite the overwhelming evidence of kidney injury in CLD patients. This study determines the transcriptomic and proteomic expression profiles of renal drug transporters in patients with defined CLD etiology.
Reagents OTA and d5-OTA were purchased from Toronto Research Chemicals. Carboxymethyl cellulose, thioacetamide, and sodium deoxycholate were purchased from Sigma Aldrich. Liquid chromatography-mass spectrometry (LC-MS)-grade acetonitrile, water, ethyl acetate, and formic acid were purchased from Fisher Chemical. Sequencing-grade trypsin was purchased from Promega, Inc.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
